Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 04/22/2025 at 06:59, 11 months 1 day ago

Biophytis targets mobility restoration in patients with obesity
Biophytis focuses on preserving muscle function in obesity patients treated with GLP-1 therapies by developing BIO101. The aim is to improve quality of weight loss and mobility

Biophytis BIO101 Obesity Muscle Function GLP-1 Therapies
BRIEF

published on 04/09/2025 at 07:05, 11 months 14 days ago

Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment

Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
BRIEF

published on 04/09/2025 at 07:05, 11 months 14 days ago

Biophytis lance la phase 2 de l'essai clinique OBA pour l'obésité

Investissement Biophytis Essai Clinique BIO101 Obésité
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 14 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development

Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial
REGULATED PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 14 days ago

Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
Biophytis confirme le lancement de l'essai clinique de Phase 2 OBA dans l'obésité en 2025, avec BIO101. Recherche d'un partenaire pharmaceutique pour le développement et le lancement du produit aux États-Unis

Biophytis Essai Clinique BIO101 Obésité Partenaire Pharmaceutique
PRESS RELEASE

published on 04/09/2025 at 06:59, 11 months 14 days ago

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients

Biophytis BIO101 Obesity Muscle Strength Phase 2 OBA Clinical Trial
BRIEF

published on 03/28/2025 at 22:05, 11 months 25 days ago

Biophytis Finalizes €2.6 Million Private Placement

Private Placement Biophytis Warrants New Shares Euronext Growth
BRIEF

published on 03/28/2025 at 22:05, 11 months 25 days ago

Biophytis finalise un placement privé de 2,6 millions d'euros

Biophytis Biotechnologie Placement Privé Euronext Growth Actions Nouvelles
REGULATED PRESS RELEASE

published on 03/28/2025 at 22:00, 11 months 25 days ago

Biophytis announces the settlement and delivery of its €2.6 million private placement
Biophytis announces the settlement and delivery of its €2.6 million private placement. New shares admitted for trading on Euronext Growth. Maxim Group LLC and Invest Securities involved in the transaction

Private Placement Biophytis Euronext Growth Maxim Group LLC Settlement
REGULATED PRESS RELEASE

published on 03/28/2025 at 22:00, 11 months 25 days ago

Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros. Les actions seront cotées sur Euronext Growth. Maxim Group LLC et Invest Securities ont agi en tant qu'agents de placement

Biophytis Placement Privé Euronext Growth INVEST SECURITIES Maxim Group LLC

Published on 03/23/2026 at 02:00, 5 hours 56 minutes ago

FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 23:00, 2 days 8 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 10 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 10 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 18 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock

View all ACCESSWIRE

Published on 03/23/2026 at 07:46, 10 minutes ago

Delivery Hero to sell Taiwan food delivery operations to Grab for USD 600 million
Published on 03/23/2026 at 07:30, 26 minutes ago

Nordex Group receives new order from Serbia for 70 MW
Published on 03/23/2026 at 07:30, 26 minutes ago

Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Published on 03/23/2026 at 07:30, 26 minutes ago

Salzgitter Group delivers pretax result close to breakeven
Published on 03/23/2026 at 07:30, 26 minutes ago

q.beyond intends to grow revenues to € 250 million by 2028 – “2028 Strategy” leverages sector focus, AI, and internationalisation

View all EQS

Published on 03/20/2026 at 19:00, 2 days 12 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 12 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 13 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 13 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 2 days 14 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News